Advaxis is actively seeking commercialization partners for the license and development of its proprietary investigational Lm Technology^™ immunotherapies.

Advaxis has created more than 20 distinct immunotherapy candidates based on its proprietary platform that are available for partnering in anti-PD-1 combination therapy, recurrent cervical cancer, HPV-associated head and neck cancer, HPV-associated anal cancer, prostate cancer, HER2 expressing tumors, and others.

Interested parties may contact:

Gregory T. Mayes
Executive Vice President and Chief Operating Officer
Advaxis, Inc.
305 College Rd East
Princeton, NJ 0854
mayes@advaxis.com
609-452-9813